Home › Cerenis Receives EMA Orphan Drug Designations For CER-001 For The Treatment Of ApoA-I And ABCA-1 Deficiencies
 

Keywords :   


Cerenis Receives EMA Orphan Drug Designations For CER-001 For The Treatment Of ApoA-I And ABCA-1 Deficiencies

2014-09-03 12:18:47| drugdiscoveryonline Home Page

Cerenis Therapeutics, the biopharmaceutical company developing CER-001, an engineered human apoA-I-containing pre-beta HDL mimetic, for the treatment of cardiovascular disease, recently announced that it has received two separate Orphan Drug Designations from the European Medicines Agency (EMA) for the use of CER-001 in the treatment of patients with rare genetic defects in HDL synthesis/maturation pathways, specifically apoA-I deficiency and ABCA1 deficiency

Tags: treatment drug receives deficiencies

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
21.05Estée Lauder Companies Presents Research at the Society for Investigative Dermatology Annual ...
21.05Dove Launches Whole Body Deodorants for 72-Hour Odor Protection
21.05Drowsy Sleep Co Launches Eyelash Protecting Mask
21.05Growth Opportunities in Upcycled Ingredients Anticipated Through 2032
21.05Superior Environmental Solutions Acquires Arrowhead Environmental Services
21.05Kinderhook Partners with Apex Waste Solutions and Acquires Materials Management Company and All American Disposal
21.05Liebherr Appoints Hobgood as New GM of Corporate Responsibility and Sustainability
21.05Tennessee Recycling Center Closing Due to Continued Dumping of Un-Recyclable Materials
More »